HIF1A and neoplasm: The current work found that the downstream targets of HIF-1α activity, metabolic markers Ang2, GLUT1, LDHA, and PDK1, which equip the tumor for survival and growth under hypoxic conditions (43, 44), were also downregulated by anlotinib plus bevacizumab.